• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B 细胞信号识别分子——信号转导及其与配体结合的最新研究进展。

B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.

机构信息

Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.

出版信息

Front Immunol. 2018 Dec 3;9:2820. doi: 10.3389/fimmu.2018.02820. eCollection 2018.

DOI:10.3389/fimmu.2018.02820
PMID:30559744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6286995/
Abstract

CD22 and Siglec-G are members of the Siglec family. Both are inhibitory co-receptors on the surface of B cells and inhibit B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. CD22 functions predominantly as an inhibitor on conventional B cells, while Siglec-G is an important inhibitor on the B1a-cell subset. These two B-cell Siglecs do not only inhibit initial signaling, but also have an important function in preventing autoimmunity, as double deficient mice develop a lupus-like phenotype with age. Siglecs are characterized by their conserved ability to bind terminal sialic acid of glycans on the cell surface, which is important to regulate the inhibitory role of Siglecs. While CD22 binds α2,6-linked sialic acids, Siglec-G can bind both α2,6-linked and α2,3-linked sialic acids. Interestingly, ligand binding is differentially regulating the ability of CD22 and Siglec-G to control B-cell activation. Within the last years, quite a few studies focused on the different functions of B-cell Siglecs and the interplay of ligand binding and signal inhibition. This review summarizes the role of CD22 and Siglec-G in regulating B-cell receptor signaling, membrane distribution with the importance of ligand binding, preventing autoimmunity and the role of CD22 beyond the naïve B-cell stage. Additionally, this review article features the long time discussed interaction between CD45 and CD22 with highlighting recent data, as well as the interplay between CD22 and Galectin-9 and its influence on B-cell receptor signaling. Moreover, therapeutical approaches targeting human CD22 will be elucidated.

摘要

CD22 和 Siglec-G 是 Siglec 家族的成员。它们都是 B 细胞表面的抑制性共受体,抑制 B 细胞受体诱导的信号转导,其特征是抑制钙动员和细胞激活。CD22 主要作为常规 B 细胞的抑制剂发挥作用,而 Siglec-G 是 B1a 细胞亚群的重要抑制剂。这两种 B 细胞 Siglec 不仅抑制初始信号转导,而且在预防自身免疫方面具有重要功能,因为双缺陷小鼠随着年龄的增长会发展出狼疮样表型。Siglecs 的特征是它们能够结合细胞表面糖链末端唾液酸的保守能力,这对于调节 Siglecs 的抑制作用很重要。虽然 CD22 结合α2,6 连接的唾液酸,但 Siglec-G 可以结合α2,6 连接和α2,3 连接的唾液酸。有趣的是,配体结合以不同的方式调节 CD22 和 Siglec-G 控制 B 细胞激活的能力。在过去的几年中,相当多的研究集中在 B 细胞 Siglecs 的不同功能以及配体结合和信号抑制的相互作用上。这篇综述总结了 CD22 和 Siglec-G 在调节 B 细胞受体信号转导、膜分布以及配体结合的重要性、预防自身免疫和 CD22 在幼稚 B 细胞阶段之外的作用。此外,本文综述还介绍了 CD45 和 CD22 之间长期讨论的相互作用,重点介绍了最近的数据,以及 CD22 和半乳糖凝集素-9 之间的相互作用及其对 B 细胞受体信号转导的影响。此外,还将阐明针对人 CD22 的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/079766406dde/fimmu-09-02820-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/1ee74de81932/fimmu-09-02820-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/9fd412750764/fimmu-09-02820-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/079766406dde/fimmu-09-02820-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/1ee74de81932/fimmu-09-02820-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/9fd412750764/fimmu-09-02820-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b9/6286995/079766406dde/fimmu-09-02820-g0003.jpg

相似文献

1
B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.B 细胞信号识别分子——信号转导及其与配体结合的最新研究进展。
Front Immunol. 2018 Dec 3;9:2820. doi: 10.3389/fimmu.2018.02820. eCollection 2018.
2
CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.CD22和唾液酸结合免疫球蛋白样凝集素G(Siglec-G)通过唾液酸配体结合调节B细胞信号传导的抑制作用,并控制B细胞的耐受性。
Glycobiology. 2014 Sep;24(9):807-17. doi: 10.1093/glycob/cwu066. Epub 2014 Jul 6.
3
Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.鼠类红细胞缺乏 B 细胞 Siglec 的配体,这使得红细胞表面抗原能够强烈激活 B 细胞。
J Immunol. 2018 Feb 1;200(3):949-956. doi: 10.4049/jimmunol.1701257. Epub 2017 Dec 29.
4
Sialic Acid Ligand Binding of CD22 and Siglec-G Determines Distinct B Cell Functions but Is Dispensable for B Cell Tolerance Induction.唾液酸配体与 CD22 和 Siglec-G 的结合决定了不同的 B 细胞功能,但对于诱导 B 细胞耐受是可有可无的。
J Immunol. 2018 Oct 1;201(7):2107-2116. doi: 10.4049/jimmunol.1800296. Epub 2018 Aug 24.
5
The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.B 细胞 Siglecs 的配体相互作用参与了对唾液酸化自身抗原的自身免疫的预防,以及信号转导能力 B 细胞的质量控制。
Int Immunol. 2023 Oct 6;35(10):461-473. doi: 10.1093/intimm/dxad030.
6
CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.CD22 结合合成唾液酸调节 B 淋巴细胞增殖的 CD22 配体依赖性和非依赖性途径,并增强小鼠的抗体产生。
Front Immunol. 2018 Apr 19;9:820. doi: 10.3389/fimmu.2018.00820. eCollection 2018.
7
Ligand Recognition Determines the Role of Inhibitory B Cell Co-receptors in the Regulation of B Cell Homeostasis and Autoimmunity.配体识别决定了抑制性 B 细胞共受体在调节 B 细胞内稳态和自身免疫中的作用。
Front Immunol. 2018 Oct 2;9:2276. doi: 10.3389/fimmu.2018.02276. eCollection 2018.
8
CD22 Controls Germinal Center B Cell Receptor Signaling, Which Influences Plasma Cell and Memory B Cell Output.CD22 控制生发中心 B 细胞受体信号转导,进而影响浆细胞和记忆 B 细胞的输出。
J Immunol. 2021 Aug 15;207(4):1018-1032. doi: 10.4049/jimmunol.2100132. Epub 2021 Jul 30.
9
CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions.CD22与唾液酸结合免疫球蛋白样凝集素G:功能各异的B细胞抑制性受体。
Immunol Rev. 2009 Jul;230(1):128-43. doi: 10.1111/j.1600-065X.2009.00801.x.
10
Identification of Siglec Ligands Using a Proximity Labeling Method.利用邻近标记法鉴定 Siglec 配体。
J Proteome Res. 2017 Oct 6;16(10):3929-3941. doi: 10.1021/acs.jproteome.7b00625. Epub 2017 Sep 22.

引用本文的文献

1
Insights into the transcriptional regulation of CD22 in B cell chronic lymphocytic leukemia.B细胞慢性淋巴细胞白血病中CD22转录调控的研究进展
J Biol Chem. 2025 Apr;301(4):108386. doi: 10.1016/j.jbc.2025.108386. Epub 2025 Mar 5.
2
Senescent Cell-Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance.衰老细胞衍生的细胞外囊泡通过协调免疫监视来抑制癌症复发。
Cancer Res. 2025 Mar 3;85(5):859-874. doi: 10.1158/0008-5472.CAN-24-0875.
3
The role of sialidase Neu1 in respiratory diseases.神经氨酸酶 Neu1 在呼吸疾病中的作用。

本文引用的文献

1
Sialic Acid Ligand Binding of CD22 and Siglec-G Determines Distinct B Cell Functions but Is Dispensable for B Cell Tolerance Induction.唾液酸配体与 CD22 和 Siglec-G 的结合决定了不同的 B 细胞功能,但对于诱导 B 细胞耐受是可有可无的。
J Immunol. 2018 Oct 1;201(7):2107-2116. doi: 10.4049/jimmunol.1800296. Epub 2018 Aug 24.
2
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病:改变复发难治性疾病的治疗方式
Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x.
3
Galectin-9 binds IgM-BCR to regulate B cell signaling.
Respir Res. 2024 Mar 19;25(1):134. doi: 10.1186/s12931-024-02763-9.
4
Neu5Gc regulates decidual macrophages leading to abnormal embryo implantation.Neu5Gc 调节蜕膜巨噬细胞导致胚胎着床异常。
Genes Immun. 2024 Apr;25(2):149-157. doi: 10.1038/s41435-024-00268-5. Epub 2024 Mar 18.
5
The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.Siglecs和唾液酸作为肿瘤免疫治疗生物标志物和治疗靶点的潜力
Cancers (Basel). 2024 Jan 10;16(2):289. doi: 10.3390/cancers16020289.
6
Combinatorial multimer staining and spectral flow cytometry facilitate quantification and characterization of polysaccharide-specific B cell immunity.组合多聚体染色和光谱流式细胞术促进多糖特异性 B 细胞免疫的定量和表征。
Commun Biol. 2023 Oct 28;6(1):1095. doi: 10.1038/s42003-023-05444-3.
7
A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners.一种用于研究免疫球蛋白糖结合伙伴的光亲和聚糖标记方法。
Glycobiology. 2023 Oct 29;33(9):732-744. doi: 10.1093/glycob/cwad055.
8
The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.抑制性受体 Siglec-G 控制慢性淋巴细胞白血病的严重程度。
EMBO Rep. 2023 Aug 3;24(8):e56420. doi: 10.15252/embr.202256420. Epub 2023 Jul 10.
9
NEU1 and NEU3 enzymes alter CD22 organization on B cells.NEU1和NEU3酶改变B细胞上CD22的组织形式。
Biophys Rep (N Y). 2022 Jul 22;2(3):100064. doi: 10.1016/j.bpr.2022.100064. eCollection 2022 Sep 14.
10
Glycobiology of rheumatic diseases.风湿性疾病的糖生物学。
Nat Rev Rheumatol. 2023 Jan;19(1):28-43. doi: 10.1038/s41584-022-00867-4. Epub 2022 Nov 23.
半乳糖凝集素-9 通过结合 IgM-BCR 来调节 B 细胞信号转导。
Nat Commun. 2018 Aug 17;9(1):3288. doi: 10.1038/s41467-018-05771-8.
4
Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans.半乳糖凝集素-9 抑制 B 细胞受体信号转导,并受 N-糖基分支的调节。
Nat Commun. 2018 Aug 17;9(1):3287. doi: 10.1038/s41467-018-05770-9.
5
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.泊马度胺治疗复发/难治性毛细胞白血病。
Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.
6
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.来自一项针对复发/难治性急性淋巴细胞白血病的英妥昔单抗奥佐米星与标准疗法的 3 期随机对照试验的患者报告结局。
Cancer. 2018 May 15;124(10):2151-2160. doi: 10.1002/cncr.31317. Epub 2018 Mar 6.
7
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.依帕珠单抗,一种抗 CD22 单克隆 IgG 抗体,在伴有干燥综合征的系统性红斑狼疮患者中的疗效:来自 EMBODY 试验的事后分析。
Arthritis Rheumatol. 2018 May;70(5):763-773. doi: 10.1002/art.40425. Epub 2018 Apr 12.
8
Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.鼠类红细胞缺乏 B 细胞 Siglec 的配体,这使得红细胞表面抗原能够强烈激活 B 细胞。
J Immunol. 2018 Feb 1;200(3):949-956. doi: 10.4049/jimmunol.1701257. Epub 2017 Dec 29.
9
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.CD22 靶向 CAR T 细胞可诱导对 CD19 靶向 CAR 免疫疗法初治或耐药的 B-ALL 缓解。
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
10
Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2,6 sialic acid-dependent and -independent interactions.CD22/Siglec-2顺式配体的邻近标记揭示了逐步的α2,6唾液酸依赖性和非依赖性相互作用。
Biochem Biophys Res Commun. 2018 Jan 1;495(1):854-859. doi: 10.1016/j.bbrc.2017.11.086. Epub 2017 Nov 14.